Ligand Pharmaceuticals LGND Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $274.48M+51.2% | $268.09M+60.4% | $251.23M+64.8% | $187.58M+40.5% | $181.49M+53.4% | ||
| $33.25M-49.3% | $81.18M+279% | $82.1M+265% | $66.75M+199% | $65.54M+175% | ||
| $94.48M+9.2% | $92.45M+17.5% | $93.03M+34.7% | $89.06M+50.4% | $86.5M+63.6% | ||
| $179.89M-26.1% | $227.09M+19.7% | $233.71M+38.5% | $221.85M+46.0% | $243.3M+103% | ||
| $94.59M+253% | $41M+281% | $17.52M— | -$34.27M— | -$61.81M— | ||
| 34.5%+68.5pp | 15.3%+28.8pp | 7%— | -18.3%— | -34.1%— | ||
| $5.6M+48.8% | $4.72M+55.5% | $3.81M+67.2% | $3.64M+136% | $3.76M+575% | ||
| $18.54M+138% | $13.66M+69.6% | $9.2M+17.7% | $6.67M-23.6% | $7.81M-5.9% | ||
| $90.3M— | $117.96M— | —— | —— | —— | ||
| $16.24M+113% | $0— | -$102.55M— | -$107.94M— | -$123.14M— | ||
| $184.88M— | $158.96M— | —— | —— | —— | ||
| $31.32M— | $34.51M— | —— | —— | —— | ||
| $153.56M+216% | $124.45M+3,187% | $48.58M+7.4% | -$75.86M-280% | -$132.62M-238% | ||
| 55.9%+129pp | 46.4%+48.8pp | 19.3%-10.3pp | -40.4%-72.0pp | -73.1%-155pp | ||
| $7.43+204% | $5.89+3,045% | $2.03-19.1% | -$4.04-275% | -$7.16-235% | ||
| $7.90+210% | $6.36+4,992% | $2.31-12.5% | -$4.07-267% | -$7.20-232% | ||
| 80.7M+9.2% | 80M+9.9% | 78M+7.9% | 75.8M+6.4% | 73.9M+4.1% | ||
| 78.1M+5.7% | 77.4M+6.9% | 76.4M+6.9% | 75.2M+6.8% | 73.9M+6.1% | ||
| $32.55M-1.5% | $32.71M-0.8% | $32.87M-0.5% | $33.03M0.0% | $33.03M-0.8% | ||
| $12.97M-0.5% | $14.55M+31.4% | $14.39M+45.7% | $13.04M+19.5% | $13.04M+34.8% | ||
| -$443K+97.0% | $0+100% | -$7.24M+7.3% | -$15.89M— | -$14.61M— | ||
| $41.44M— | $90.67M— | —— | —— | —— | ||
| —— | —— | -$8.28M— | -$17.31M— | -$52.2M— | ||
| $274.48M+51.2% | $268.09M+60.4% | $251.23M+64.8% | $187.58M+40.5% | $181.49M+53.4% | ||
| $94.59M+253% | $41M+281% | $17.52M+311% | -$34.27M-917% | -$61.81M-390% | ||
| $127.81M+581% | $74.78M+492% | $51.71M+30.0% | $647K-98.4% | -$26.57M-147% | ||
| $127.81M+581% | $74.78M+492% | $51.71M+30.0% | $647K-98.4% | -$26.57M-147% | ||
| 46.6%+61.2pp | 27.9%+20.3pp | 20.6%-5.5pp | 0.3%-29.1pp | -14.6%-62.9pp | ||
| $94.59M+253% | $41M+281% | $17.52M+311% | -$34.27M-917% | -$61.81M-390% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Ligand Pharmaceuticals's profit margins?
- Gross margin is 91.9% and operating margin is 34.5%, with a 55.9% net margin.
- Where does Ligand Pharmaceuticals's income statement data come from?
- Every line is extracted from Ligand Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.